OVID

Ovid Therapeutics Inc

Add to Watchlist

Advanced Chart

0.619

-0.074(-10.678%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.69985

Open

0.6997

VWAP

0.64

Vol

1.08M

Mkt Cap

43.98M

Low

0.6097

Amount

688.36K

EV/EBITDA(TTM)

Total Shares

70.94M

985.23K

EV/OCF(TTM)

P/S(TTM)

80.20

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

93.17K

-44.87%

78.00K

-54.91%

71.83K

-5.49%

Estimates Revision

The market is revising Upward the revenue expectations for Ovid Therapeutics Inc. (OVID) for FY2025, with the revenue forecasts being adjusted by 40.72% over the past three months. During the same period, the stock price has changed by 76.71%.

Revenue Estimates for FY2025

Revise Upward

+40.72%

In Past 3 Month

Stock Price

Go Up

+76.71%

In Past 3 Month

5 Analyst Rating

357.56% Upside

Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 2.83 USD with a low forecast of 1.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

357.56% Upside

Current: 0.619

Low

1.50

Averages

2.83

High

4.00

357.56% Upside

Current: 0.619

Low

1.50

Averages

2.83

High

4.00

H.C. Wainwright

Buy

downgrade

2025-05-27

Reason

H.C. Wainwright

Price Target

2025-05-27

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Ovid Therapeutics to $1.50 from $2 and keeps a Buy rating on the shares. Ovid currently trades at a negative enterprise value and remains slated to deliver multiple potential value inflection points over the next 12 months, the analyst tells investors in a research note.

BTIG

Thomas Shrader

Strong Buy

Maintains

$5 → $4

2025-03-24

Reason

BTIG

Thomas Shrader

Price Target

$5 → $4

2025-03-24

Maintains

Strong Buy

Reason

BTIG analyst Thomas Shrader lowered the firm's price target on Ovid Therapeutics to $4 from $5 and keeps a Buy rating on the shares after its Q4 results. The management team is leaving no stone unturned to try to maximize the chances that future steps will be productive, the analyst tells investors in a research note. For OV329, topline biomarker data are expected in Q3, and this readout is expected to benefit from the growing use of TMS in measuring gross neuronal excitability in the cortex of patients, the firm added, stating however that its reduced price target reflects the development of Soticlestat having been stopped.

Wedbush

Laura Chico

Buy

Maintains

$4 → $3

2025-03-12

Reason

Wedbush

Laura Chico

Price Target

$4 → $3

2025-03-12

Maintains

Buy

Reason

Wedbush analyst Laura Chico lowered the firm's price target on Ovid Therapeutics to $3 from $4 and keeps an Outperform rating on the shares. The firm notes the company's management reiterated their expectation for cash runway into second half of 2026, and now look for preliminary Phase 1 OV329 TMS, MRS data to arrive in Q3 2025. At this stage, Wedbush looks for signs of increasing GABAergic activity that can be delivered in a safe manner. Initial OV350 clinical data is also expected in Q4 2025; however, the firm continues to leave the KCC2 program as upside to its estimates.

Oppenheimer

Francois Brisebois

Hold

Buy

Upgrades

2025-01-29

Reason

Oppenheimer

Francois Brisebois

Price Target

2025-01-29

Upgrades

Hold

Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2024-12-04

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2024-12-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2024-09-30

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2024-09-30

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ovid Therapeutics Inc (OVID.O) is -0.99, compared to its 5-year average forward P/E of -2.94. For a more detailed relative valuation and DCF analysis to assess Ovid Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.94

Current PE

-0.99

Overvalued PE

-0.28

Undervalued PE

-5.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.36

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

6.38

Undervalued EV/EBITDA

-5.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

371.35

Current PS

143.67

Overvalued PS

1041.01

Undervalued PS

-298.31

Financials

Annual

Quarterly

FY2025Q1

YoY :

-12.16%

130.00K

Total Revenue

FY2025Q1

YoY :

-27.94%

-12.55M

Operating Profit

FY2025Q1

YoY :

-12.48%

-10.24M

Net Income after Tax

FY2025Q1

YoY :

-17.65%

-0.14

EPS - Diluted

FY2025Q1

YoY :

-38.46%

-10.28M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-14.96%

-9.07K

FCF Margin - %

FY2025Q1

YoY :

-0.36%

-7.87K

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

5.1K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

5.0K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 219.68% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

394.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

5.1K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

5.0K

USD

Months

0-12

0.0

USD

Months

OVID News & Events

Events Timeline

2025-06-25 (ET)

2025-06-25

08:09:57

Ovid enters agreement with Immedica for sale of future ganaxolone royalties

2025-05-13 (ET)

2025-05-13

08:03:55

Ovid Therapeutics sees cash runway into 2H26

2025-05-13

08:03:24

Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)

News

8.5

06-25NASDAQ.COM

Ovid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market

1.0

06-05Newsfilter

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

9.5

05-13Newsfilter

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

People Also Watch

Ampco-Pittsburgh Corp

Maia Biotechnology Inc

Grove Collaborative Holdings Inc

Crown LNG Holdings Ltd

Xilio Therapeutics Inc

Permianville Royalty Trust

LakeShore Biopharma Co Ltd

1.150

USD

-12.21%

FAQ

What is Ovid Therapeutics Inc (OVID) stock price today?

The current price of OVID is 0.6185 USD — it has decreased -10.68 % in the last trading day.

OVID

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

OVID News & Events

Events Timeline

News

People Also Watch

FAQ

What is Ovid Therapeutics Inc (OVID) stock price today?

What is Ovid Therapeutics Inc (OVID)'s business?

What is the price predicton of OVID Stock?

What is Ovid Therapeutics Inc (OVID)'s revenue for the last quarter?

What is Ovid Therapeutics Inc (OVID)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Ovid Therapeutics Inc (OVID)'s fundamentals?

How many employees does Ovid Therapeutics Inc (OVID). have?

What is Ovid Therapeutics Inc (OVID) market cap?